Log in

NASDAQ:SRDXSurModics Stock Price, Forecast & News

$41.86
+0.53 (+1.28 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$41.06
Now: $41.86
$42.07
50-Day Range
$36.13
MA: $40.50
$44.74
52-Week Range
$22.06
Now: $41.86
$49.00
Volume31,100 shs
Average Volume65,999 shs
Market Capitalization$569.71 million
P/E Ratio85.43
Dividend YieldN/A
Beta0.98
Surmodics, Inc., together with its subsidiaries, provides medical devices and in vitro diagnostic technologies to the healthcare industry in the United States and internationally. The company operates through two segments, Medical Device and In Vitro Diagnostics. The Medical Device segment designs, develops, and manufactures interventional medical devices primarily for the peripheral vascular market; and offers surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device for the coronary, peripheral, neuro-vascular, urology, and other markets. The Vitro Diagnostics segment provides stabilization products, substrates, antigens, and surface coatings to diagnostics customers; and manufactures or sells components for in vitro diagnostic immunoassay and molecular tests, as well as surface coatings to the diagnostic, biomedical research, and life science markets. Surmodics, Inc. was founded in 1979 and is headquartered in Eden Prairie, Minnesota.
Read More
SurModics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.37 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:SRDX
CUSIP86887310
Phone952-500-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$100.08 million
Cash Flow$1.32 per share
Book Value$9.08 per share

Profitability

Net Income$7.59 million

Miscellaneous

Employees338
Market Cap$569.71 million
Next Earnings Date7/29/2020 (Estimated)
OptionableOptionable

Receive SRDX News and Ratings via Email

Sign-up to receive the latest news and ratings for SRDX and its competitors with MarketBeat's FREE daily newsletter.

SurModics (NASDAQ:SRDX) Frequently Asked Questions

How has SurModics' stock been impacted by COVID-19 (Coronavirus)?

SurModics' stock was trading at $29.91 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SRDX stock has increased by 40.0% and is now trading at $41.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SurModics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SurModics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SurModics.

When is SurModics' next earnings date?

SurModics is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for SurModics.

How were SurModics' earnings last quarter?

SurModics, Inc. (NASDAQ:SRDX) released its earnings results on Wednesday, April, 29th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.11) by $0.15. The business earned $22.82 million during the quarter, compared to analyst estimates of $22.47 million. SurModics had a net margin of 6.59% and a return on equity of 6.99%. View SurModics' earnings history.

What price target have analysts set for SRDX?

3 analysts have issued 1-year price targets for SurModics' stock. Their forecasts range from $62.00 to $76.00. On average, they anticipate SurModics' stock price to reach $68.67 in the next twelve months. This suggests a possible upside of 64.0% from the stock's current price. View analysts' price targets for SurModics.

Has SurModics been receiving favorable news coverage?

News headlines about SRDX stock have been trending neutral on Saturday, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. SurModics earned a news sentiment score of 0.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about SurModics.

Are investors shorting SurModics?

SurModics saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 397,200 shares, an increase of 23.1% from the May 31st total of 322,600 shares. Based on an average trading volume of 88,900 shares, the short-interest ratio is presently 4.5 days. Currently, 3.0% of the company's shares are sold short. View SurModics' Current Options Chain.

Who are some of SurModics' key competitors?

What other stocks do shareholders of SurModics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SurModics investors own include Gilead Sciences (GILD), Netflix (NFLX), Intel (INTC), NVIDIA (NVDA), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Uniqure (QURE), Sarepta Therapeutics (SRPT), Supernus Pharmaceuticals (SUPN) and Tandem Diabetes Care (TNDM).

Who are SurModics' key executives?

SurModics' management team includes the following people:
  • Mr. Gary R. Maharaj, CEO, Pres & Director (Age 56)
  • Mr. Timothy J. Arens, Chief Financial Officer (Age 52)
  • Mr. Bryan K. Phillips, Sr. VP of Legal, HR & Information Technology, Gen. Counsel and Sec. (Age 48)
  • Mr. Thomas A. Greaney, Chief Operating Officer of Medical Devices (Age 53)
  • Mr. Gregg S. Sutton, VP of R&D - Medical Devices (Age 59)

What is SurModics' stock symbol?

SurModics trades on the NASDAQ under the ticker symbol "SRDX."

Who are SurModics' major shareholders?

SurModics' stock is owned by a number of institutional and retail investors. Top institutional investors include Wedge Capital Management L L P NC (0.24%) and Modus Advisors LLC (0.01%). Company insiders that own SurModics stock include Gary R Maharaj, Gregg S Sutton, Joseph J Stich, Lisa Wipperman Heine and Susan E Knight. View institutional ownership trends for SurModics.

Which major investors are buying SurModics stock?

SRDX stock was purchased by a variety of institutional investors in the last quarter, including Wedge Capital Management L L P NC, and Modus Advisors LLC. View insider buying and selling activity for SurModics.

How do I buy shares of SurModics?

Shares of SRDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SurModics' stock price today?

One share of SRDX stock can currently be purchased for approximately $41.86.

How big of a company is SurModics?

SurModics has a market capitalization of $569.71 million and generates $100.08 million in revenue each year. The company earns $7.59 million in net income (profit) each year or $0.72 on an earnings per share basis. SurModics employs 338 workers across the globe.

What is SurModics' official website?

The official website for SurModics is www.surmodics.com.

How can I contact SurModics?

SurModics' mailing address is 9924 WEST 74TH STREET, EDEN PRAIRIE MN, 55344. The company can be reached via phone at 952-500-7000 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.